Search

Author/Creator Santin, Alessandro

2. EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma. (4th December 2022)

Authors:
Harold, Justin; Manavella, Diego; Bellone, Stefania; Siegel, Eric; Hartwich, Tobias; Zammataro, Luca; Mutlu, Levent; Altwerger, Gary; Menderes, Gulden; Ratner, Elena; Huang, Gloria; Clark, Mitchell; Andikyan, Vaagn; Azodi, Masoud; Schwartz, Peter; Alexandrov, Ludmil; Santin, Alessandro
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 3
Page Start:
A51
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: study 309/keynote-775. (4th December 2022)

Authors:
Makker, Vicky; Colombo, Nicoletta; Herráez, Antonio Casado; Monk, Bradley; Mackay, Helen; Santin, Alessandro; Miller, David; Moore, Richard; Ray-Coquard, Isabelle; Shapira-Frommer, Ronnie; Ushijima, Kimio; Yonemori, Kan; Kim, Yong Man; Alia, Eva Guerra; Sanli, Ulus; Xie, Ran; Zale, Melissa; Mcken...
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 3
Page Start:
A11
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. Issue 9 (20th March 2022)

Authors:
Powell, Matthew A.; Filiaci, Virginia L.; Hensley, Martee L.; Huang, Helen Q.; Moore, Kathleen N.; Tewari, Krishnansu S.; Copeland, Larry J.; Secord, Angeles A.; Mutch, David G.; Santin, Alessandro; Warshal, David P.; Spirtos, Nick M.; DiSilvestro, Paul A.; Ioffe, Olga B.; Miller, David S.
Journal:
Journal of clinical oncology
Issue:
Volume 40:Issue 9(2022)
Page Start:
968
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Issue 1 (December 2015)

Authors:
Ferrari, Francesca; Bellone, Stefania; Black, Jonathan; Schwab, Carlton; Lopez, Salvatore; Cocco, Emiliano; Bonazzoli, Elena; Predolini, Federica; Menderes, Gulden; Litkouhi, Babak; Ratner, Elena; Silasi, Dan-Arin; Azodi, Masoud; Schwartz, Peter; Santin, Alessandro
Journal:
Journal of experimental & clinical cancer research
Issue:
Volume 34:Issue 1(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗